Effects of natalizumab therapy on intrathecal antiviral antibody responses in MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 15, 2018
- Accepted in final form July 31, 2019
- First Published September 25, 2019.
Author Disclosures
- Fabienne Largey, PhD,
- Ivan Jelcic, PhD,
- Mireia Sospedra, PhD,
- Christoph Heesen, MD,
- Roland Martin, MD and
- Ilijas Jelcic, MD
- Fabienne Largey, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Celgene GmbH, Medical Affairs, 2 years (employment started after end of study)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ivan Jelcic, PhD,
Dr. Ivan Jelcic received compensation for serving on a scientific advisory board by Sanofi Genzyme in 2018.
NONE
Dr. Ivan Jelcic received speaker honoraria from the Swiss Society of Multiple Sclerosis (non-profit) in 2018.
NONE
Dr. Ivan Jelcic is listed as inventor on a patent of human monoclonal antibodies against JCPyV VP1 for the treatment of PML.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mireia Sospedra, PhD,
NONE
NONE
NONE
Invited editor of the special issue `Understanding and Elucidation of the Specificity of αβ-T cells`in Frontiers in Immunology
Sospedra, M., Martin, R., Planas, R., Jelcic, I., Santos, R., Pinilla, C. IMMUNODOMINANT PROTEINS AND FRAGMENTS IN AUTOIMMUNE DISEASES. EP18180326.3 (2018). Jelcic, I., Martin, R., Schippling, S., Sospedra, M., Yousef, S. POLYOMA VIRUS JC PEPTIDES AND PROTEINS IN VACCINATION AND DIAGNOSTIC APPLICATIONS WO Patent 2,013,014,134 (2013)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christoph Heesen, MD,
Ibsen Pharmaceuticals
NONE
Received speaker honoraries from Biogen, Merck, Genzyme, Novartis
International Journal of MS Care, 2014 until now
NONE
NONE
NONE
NONE
NONE
Received Research grants from Genzyme, Biogen, Roche, Novartis, Merck, Roche.
NONE
Genzyme Sanofi Aventis Biogen Novartis Merck Roche
German Minstery of Research, PI 2012-2016 Hertie Foundation, PI 2014-2016 German Innovation Fond, PI 2018-2021
NONE
NMSS
NONE
NONE
NONE
NONE
NONE
NONE
- Roland Martin, MD and
I have received personal compensation for advisory work to Biogen, Merck & Serono, Teva, Genzyme Sanofi-Aventis, CellProtect, Neuway
NONE
I have received personal compensation/honoraria for speaking at workshops or small meetings by Biogen and Merck & Serono, Novartis, Roche, Genzyme, Teva, Sanofi-Aventis.
NONE
Together with B. Bielekova, H. McFarland and T. Waldmann I am a coholder of a patent claiming the therapeutic efficacy of anti-CD25 monoclonal antibody treatment in combination with IFN-b in MS. This patent is owned by NIH, but the patent holders receive periodic royalties. I have received royalties in the last five years. I am also inventor or co-inventor on University Zurich-held patents in the context of antigen-specific tolerization with peptide-coupled cells.
NONE
NONE
I have been consulting for the Myelin Repair Foundation, The Weatherall Institute for Molecular Studies, University of Oxford, the German Research Society, and the Hertie Foundation. These are all non-profit academic or private institutions, foundations. I am a member of the Kuratorium of the Jung Foundation for Science, Hamburg, Germany, also a non-profit organization; the Swiss Multiple Sclerosis Society, also non-profit, and several other national MS societies, in each case non-profit.
NONE
NONE
NONE
Novartis has given us financial support (unrestricted grant) to examine the effects of fingolimod on immune responses against herpes viruses. Biogen has given us financial support (unrestricted grant) to study the effects of natalizumab on the intrathecal antibody response in MS. We have also received unrestricted support for the department of neuroimmunology and MS research from Roche.
Swiss National Science Foundation (throughout last 7 years). European Union Seventh Framework Program. European Research Council Advanced Grant. Clinical Research Priority Program Multiple Sclerosis of the University Zurich for the last 6 years.
NONE
NONE
I hold stock of CellProtect, a small biotech Company.
NONE
I had received royalty payments (periodically) from a NIH- Held patent on the use of anti-CD25 (daclizumab) in multiple sclerosis.
I am Co-Founder and Co-Owner of Cellerys, a startup company out of Univ. Zurich, which is pursuing antigen-specific tolerization.
NONE
NONE
- Ilijas Jelcic, MD
Neuway, Merck, Novartis and Sanofi Genzyme
NONE
Novartis, speaker honoraria
NONE
Ivan J. and R.M. are listed as inventors on a patent of the human monoclonal antibodies against JCPyV VP1 for the treatment of PML. R.M., Ilijas J. and M.S. are listed as coinventors on a patent on vaccination against PML by immunisation with JCPyV VP1 protein.
NONE
NONE
NONE
NONE
NONE
NONE
Novartis, unrestricted grant; Biogen, unrestricted grant (Biogen is the maker of Natalizumab, and has not imposed and has not tried to impose any restrictions on our submission of this work)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuroimmunology and Multiple Sclerosis Research Section (F.L., Ivan Jelcic, M.S., R.M., Ilijas Jelcic), Department of Neurology, University Hospital of Zurich, Switzerland; and Institute for Neuroimmunology and Multiple Sclerosis (inims) (C.H.), Center for Molecular Neurobiology (ZMNH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Correspondence
Dr. Ilijas Jelcic Ilijas.Jelcic{at}usz.ch
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of PlasmablastsMiriam Schlüter, Eva Oswald, Stephan Winklmeier et al.Neurology: Neuroimmunology & Neuroinflammation, July 01, 2021 -
Articles
Antigen microarrays identify CNS-produced autoantibodies in RRMSF.J. Quintana, M.F. Farez, G. Izquierdo et al.Neurology, January 18, 2012 -
Article
Natalizumab-associated progressive multifocal leukoencephalopathy in GermanyKira Blankenbach, Nicholas Schwab, Benjamin Hofner et al.Neurology, April 05, 2019 -
Articles
Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosisS.A. Sargsyan, A.J. Shearer, A.M. Ritchie et al.Neurology, March 10, 2010